Assertio Therapeutics Announces FDA Notification of Acceptance for Filing of 505(b)(2) NDA for Long-acting Cosyntropin

- February 19th, 2019

Assertio Therapeutics (NASDAQ:ASRT) has announced it has received notice of acceptance for filing from the US Food and Drug Administration (FDA) for its 505(b)(2) New Drug Application for its injectable formulation of long-acting cosyntropin. As quoted in the press release: The Company, together with its partner West Therapeutic Development, seeks approval for the use of … Continued

Assertio Therapeutics (NASDAQ:ASRT) has announced it has received notice of acceptance for filing from the US Food and Drug Administration (FDA) for its 505(b)(2) New Drug Application for its injectable formulation of long-acting cosyntropin.

As quoted in the press release:

The Company, together with its partner West Therapeutic Development, seeks approval for the use of this product as a diagnostic drug in the screening of patients presumed to have adrenocortical insufficiency.

“We are pleased to announce another positive milestone in the development of long-acting cosyntropin and in the advancement of our strategy to build a new orphan/specialty business,” said Arthur Higgins, President and Chief Executive Officer of Assertio. “The FDA’s acceptance of our filing positions us one step closer to launching a synthetic long-acting cosyntropin into the U.S. market by early 2020.”

The PDUFA (Prescription Drug User Fee Act) goal date for the completion of the FDA’s review of long-acting cosyntropin is set for October 19, 2019. This date reflects a standard 10-month review period and is consistent with management’s expectations for the 505(b)(2) filing.

Click here to read the full press release.

We found the top performing pharma stocks to watch this year

Find out more in our report
 

Leave a Reply

Your email address will not be published. Required fields are marked *